Molecular targeted therapy plays an increasingly important role in the treatment of metastatic
pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain …

Abstract Context Pheochromocytomas and paragangliomas (PPGLs) are known to be rare.
However, there is scant literature reporting their epidemiology, particularly whether the …

This article aims to review current concepts in diagnosing and managing
pheochromocytoma and paraganglioma (PPGL). Personalized genetic testing is vital, as 40 …

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors
originating from chromaffin cells, holding significant clinical importance due to their capacity …

Molecular testing for hereditary cancers has rapidly advanced over the past two decades.
Next‐generation sequencing has been widely adopted, which has made molecular testing …

Introduction. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-
DOTATOC showed efficacy in the metastatic setting of pheocromocytomas (PCCs) and …

Objective Pheochromocytoma is a rare catecholamine-producing neuroendocrine tumour
originating from the chromaffin cells of the adrenal medulla or extra-adrenal paraganglia …

Pheochromocytomas (PCCs) are rare neuroendocrine tumors that originate from chromaffin
cells in the adrenal gland. However, the cellular molecular characteristics and immune …

The routes by which foreign objects enter cells is well studied; however, their fate following
uptake has not been explored extensively. Following exposure to synchrotron-sourced (SS) …

Up to 40% of pheochromocytomas (PCCs) and paragangliomas (PGLs) are hereditary.
Germline mutations/deletions in fumarate hydratase (FH) cause hereditary leiomyomatosis …